Skip to main content

Vivaglobin FDA Approval History

FDA Approved: Yes (First approved January 9, 2006)
Brand name: Vivaglobin
Generic name: immune globulin subcutaneous (human)
Company: ZLB Behring
Treatment for: Primary Immunodeficiency Syndrome

Vivaglobin is a pasteurized, polyvalent human normal immunoglobulin for subcutaneous infusion indicated for the treatment of patients with primary immune deficiency (PID).

Development timeline for Vivaglobin

Jan  9, 2006Approval Vivaglobin Approved - ZLB Behring - Treatment for Primary Immunodeficiencies

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.